Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Small Molecules

Decision Support

Why hasn’t biopharma fully embraced continuous bioprocessing?

Traditionally, continuous processing in the biotech sector has been viewed as more complex to operate and with a higher risk of failure. With the introduction of more robust technology options for upstream and downstream processing, we have seen a resurgence of interest. Yet obstacles to adoption still exist. When we ran a roundtable discussion at a recent conference on this topic (2), several participants mentioned issues such as the lack of reliable scale-down tools for continuous processes and the need for better online process analytical technology, control and hardware reliability than is currently available. Furthermore, companies working with stable antibodies may not have the same incentives as those working with labile products, where continuous processing can be a necessity.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register